カテゴリ： GlobalData, アメリカ, 企業調査

CEL-SCI Corp (CVM)-製薬・医療分野：企業M&A・提携分析

◆英語タイトル：CEL-SCI Corp (CVM) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード：DATA8013481
◆発行会社（調査会社）：GlobalData
◆発行日：2017年11月28日
◆ページ数：79
◆レポート言語：英語
◆レポート形式：PDF
◆納品方法：Eメール
◆対象地域：アメリカ
◆産業分野：製薬・医療
◆販売価格オプション（消費税別）
Single UserUSD250 ⇒換算￥37,000見積依頼/購入/質問フォーム
Site License（同一事業所内共有可）USD500 ⇒換算￥74,000見積依頼/購入/質問フォーム
Enterprisewide License（複数事業所内共有可）USD750 ⇒換算￥111,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※本体価格が￥30,000未満のレポートにつきましては、ハンドリングチャージ￥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※GlobalData社の概要はこちらでご確認いただけます。

このエントリーをはてなブックマークに追加
LINEで送る


【レポートの概要】

Summary
CEL-SCI Corp (CEL-SCI) is a biotechnology company that carries out the research and development of new immunotherapy products for the treatment of various cancer and infectious diseases. Its core capabilities include drug discovery, research, development and manufacturing of compound biological substances. CEL-SCI’s lead candidate Multikine (leukocyte interleukin), is an investigational immunotherapy against cancer and human papilloma virus (HPV). The company is also investigating an immunotherapy (LEAPS-H1N1-DC) as a possible treatment for H1N1 in hospitalized patients and vaccines CEL-2000 and CEL-4000 for rheumatoid arthritis using its Ligand Epitope Antigen Presentation System (LEAPS) technology platform. CEL-SCI is headquartered in Vienna, Virginia, the US.

CEL-SCI Corp (CVM) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
CEL-SCI Corp, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
CEL-SCI Corp, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
CEL-SCI Corp, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
CEL-SCI Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
CEL-SCI Corp, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
CEL-SCI Corp, Pharmaceuticals & Healthcare, Deal Details 11
Partnerships 11
Cel-Sci Enters Into Co-Development Agreement With Ergomed For Multikine In HIV/HPV Co-Infected Patients With Peri-Anal Warts 11
Cel-Sci Enters Into Co-Development Agreement With Ergomed For Multikine 13
Cel-Sci Expands Co-Development Agreement with Ergomed 14
Licensing Agreements 15
CEL-SCI Enters Into Licensing Agreement With IDC-GP Pharm For Multikine 15
CEL-SCI Expands Licensing Agreement With Teva Pharma For Multikine 16
Equity Offering 17
CEL-SCI to Raise USD3.5 Million in Private Placement of Shares and Warrants 17
CEL-SCI to Raise USD2 Million in Private Placement of Shares upon Exercise of Warrants 18
CEL-SCI Raises USD1.5 Million in Private Placement of Shares and Warrants 19
CEL-SCI Raises USD1 Million in Private Placement of Shares and Warrants 21
CEL-SCI Raises USD4.3 Million in Public Offering of Shares 22
CEL-SCI Raises USD5 Million in Private Placement of Shares and Warrants 24
CEL-SCI Raises USD5 Million in Registered Direct Offering 25
Cel-Sci Raises USD11.5 Million in Public Offering of Shares and Warrants 26
Cel-Sci Raises USD16 Million in Public Offering of Shares and Warrants 28
CEL-SCI Raises USD16 Million in Public Offering of Shares and Warrants 29
Cel-Sci Raises USD6 Million in Public Offering of Shares and Warrants 30
Cel-Sci Raises USD3 Million upon Exercise of Warrants 32
Cel-Sci Completes Public Offering Of Units For US$10 Million 33
Cel-Sci Completes Public Offering Of Units For US$3.3 Million 34
Cel-Sci Completes Public Offering Of Units For US$17.8 Million 36
Cel-Sci Completes Public Offering Of Common Stock For US$11 Million 38
Cel-Sci Files Registration Statement For Public Offering Of Securities For US$50 Million 39
Cel-Sci Completes Private Placement Of Common Stock For US$6 Million 40
CEL-SCI Completes Private Placement Of Common Stock For US$5.8 Million 41
CEL-SCI Completes Registered Direct Offering Of Common Stock For US$4 Million 42
Debt Offering 44
CEL-SCI Raises USD1.2 Million in Private Placement of 4% Notes Due 2017 44
CEL-SCI Raises USD1.5 Million in Private Placement of 4% Notes Due 2017 45
CEL-SCI Corp – Key Competitors 46
CEL-SCI Corp – Key Employees 47
CEL-SCI Corp – Locations And Subsidiaries 48
Head Office 48
Recent Developments 49
Financial Announcements 49
Aug 09, 2017: CEL-SCI Reports Third Quarter Fiscal Year 2017 Financial Results 49
May 10, 2017: CEL-SCI Reports Second Quarter Fiscal Year 2017 Financial Results 50
Feb 09, 2017: CEL-SCI Reports First Quarter Fiscal 2017 Financial Results 51
Dec 14, 2016: CEL-SCI Reports Fiscal 2016 Financial Results and Clinical & Corporate Developments 52
Aug 10, 2016: CEL-SCI Reports Third Quarter Fiscal Year 2016 Financial Results 53
May 10, 2016: CEL-SCI Reports Second Quarter Fiscal Year 2016 Financial Results 54
Feb 09, 2016: CEL-SCI Reports First Quarter Fiscal 2016 Financial Results 55
Corporate Communications 56
Feb 27, 2017: CEL-SCI Announces That the NYSE MKT Approves Plan 56
Dec 09, 2016: CEL-SCI Reports on NYSE MKT Noncompliance Notice and Compliance Plan 57
Sep 06, 2016: CEL-SCI Announces Resignation of its Founder for Health Reasons 58
Government and Public Interest 59
Sep 19, 2017: CEL-SCI Announces $1.5 Million NIH SBIR Grant to Support Development of Rheumatoid Arthritis Vaccine 59
Product News 60
05/16/2017: CEL-SCI Scientist Presents Data on CEL-4000 at AAI – IMMUNOLOGY 2017 Meeting 60
04/12/2017: CEL-SCI Scientist Presents at the World Vaccine Congress 61
02/23/2016: CEO Geert Kersten Summarizes CEL-SCI Phase 3 Cancer Immunotherapy Progress in a New Video Interview 62
02/21/2017: CEL-SCI Scientist Presents New Findings for Rheumatoid Arthritis Treatment Vaccine at Conference 63
Clinical Trials 64
Jun 08, 2017: CEL-SCI Announces New Data for Its Rheumatoid Arthritis Vaccine Candidate Published in Peer Reviewed Journal 64
Nov 14, 2016: CEL-SCI Reports Preclinical Data Showing LEAPS Vaccine is Successful in Treating Rheumatoid Arthritis 65
Oct 21, 2016: CEL-SCI Provides Update on Partial Clinical Hold on Phase 3 Clinical Trial 66
Sep 26, 2016: CEL-SCI Reports Clinical Hold on Head and Neck Cancer Study 67
Sep 02, 2016: CEL-SCI Reports Monthly Patient Enrollment in August for Its Phase 3 Head and Neck Cancer Trial 68
Aug 01, 2016: CEL-SCI Reports Monthly Patient Enrollment in July for Its Phase 3 Head and Neck Cancer Trial 69
Jul 05, 2016: CEL-SCI Reports Monthly Patient Enrollment in June for Its Phase 3 Head and Neck Cancer Trial 70
Jun 01, 2016: CEL-SCI Reports Monthly Patient Enrollment in May for Its Phase 3 Head and Neck Cancer Trial 71
May 02, 2016: CEL-SCI Reports Record Monthly Patient Enrollment in April for Its Phase 3 Head and Neck Cancer Trial 72
Apr 01, 2016: CEL-SCI Reports Monthly Patient Enrollment in March for Its Phase 3 Head and Neck Cancer Trial 73
Mar 01, 2016: CEL-SCI Reports Monthly Patient Enrollment in February for Its Phase 3 Head and Neck Cancer Trial 74
Feb 01, 2016: CEL-SCI Reports Monthly Patient Enrollment in January for Its Phase 3 Head and Neck Cancer Trial 75
Jan 08, 2016: Cel-Sci Summarizes Significant Accomplishments In 2015 And Positive Momentum For 2016 76
Jan 05, 2016: CEL-SCI Reports Record Year for Patient Enrollment with 75% Increase in Its Global Phase 3 Head and Neck Cancer Trial 78
Appendix 79
Methodology 79
About GlobalData 79
Contact Us 79
Disclaimer 79

List of Tables
CEL-SCI Corp, Pharmaceuticals & Healthcare, Key Facts, 2016 2
CEL-SCI Corp, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
CEL-SCI Corp, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
CEL-SCI Corp, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
CEL-SCI Corp, Deals By Therapy Area, 2011 to YTD 2017 9
CEL-SCI Corp, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Cel-Sci Enters Into Co-Development Agreement With Ergomed For Multikine In HIV/HPV Co-Infected Patients With Peri-Anal Warts 11
Cel-Sci Enters Into Co-Development Agreement With Ergomed For Multikine 13
Cel-Sci Expands Co-Development Agreement with Ergomed 14
CEL-SCI Enters Into Licensing Agreement With IDC-GP Pharm For Multikine 15
CEL-SCI Expands Licensing Agreement With Teva Pharma For Multikine 16
CEL-SCI to Raise USD3.5 Million in Private Placement of Shares and Warrants 17
CEL-SCI to Raise USD2 Million in Private Placement of Shares upon Exercise of Warrants 18
CEL-SCI Raises USD1.5 Million in Private Placement of Shares and Warrants 19
CEL-SCI Raises USD1 Million in Private Placement of Shares and Warrants 21
CEL-SCI Raises USD4.3 Million in Public Offering of Shares 22
CEL-SCI Raises USD5 Million in Private Placement of Shares and Warrants 24
CEL-SCI Raises USD5 Million in Registered Direct Offering 25
Cel-Sci Raises USD11.5 Million in Public Offering of Shares and Warrants 26
Cel-Sci Raises USD16 Million in Public Offering of Shares and Warrants 28
CEL-SCI Raises USD16 Million in Public Offering of Shares and Warrants 29
Cel-Sci Raises USD6 Million in Public Offering of Shares and Warrants 30
Cel-Sci Raises USD3 Million upon Exercise of Warrants 32
Cel-Sci Completes Public Offering Of Units For US$10 Million 33
Cel-Sci Completes Public Offering Of Units For US$3.3 Million 34
Cel-Sci Completes Public Offering Of Units For US$17.8 Million 36
Cel-Sci Completes Public Offering Of Common Stock For US$11 Million 38
Cel-Sci Files Registration Statement For Public Offering Of Securities For US$50 Million 39
Cel-Sci Completes Private Placement Of Common Stock For US$6 Million 40
CEL-SCI Completes Private Placement Of Common Stock For US$5.8 Million 41
CEL-SCI Completes Registered Direct Offering Of Common Stock For US$4 Million 42
CEL-SCI Raises USD1.2 Million in Private Placement of 4% Notes Due 2017 44
CEL-SCI Raises USD1.5 Million in Private Placement of 4% Notes Due 2017 45
CEL-SCI Corp, Key Competitors 46
CEL-SCI Corp, Key Employees 47

★海外企業調査レポート[CEL-SCI Corp (CVM)-製薬・医療分野：企業M&A・提携分析]についてメールでお問い合わせはこちら
■おすすめ企業レポート■
  • Silicon Laboratories Inc (SLAB)：企業の財務・戦略的SWOT分析
    Silicon Laboratories Inc (SLAB) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weak …
  • PharmaCyte Biotech Inc (PMCB)：企業の財務・戦略的SWOT分析
    Summary PharmaCyte Biotech Inc (PharmaCyte), formerly Nuvilex Inc, is a clinical stage biotechnology company that develops and commercializes treatments for cancer and diabetes. The company offers technology is used for the treatment of advanced and inoperable pancreatic cancer and diabetes. It deve …
  • Oriola-KD Oyj (OKDBV)：企業の財務・戦略的SWOT分析
    Oriola-KD Oyj (OKDBV) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • QPS Austria GmbH-製薬・医療分野：企業M&A・提携分析
    Summary QPS Austria GmbH (QPS), a subsidiary of QPS Holdings LLC, is a contract research organization that performs preclinical and clinical research. The company offers in vivo services which involves generating, characterizing and maintaining transgenic disease models and use them for drug testing …
  • Charles River Laboratories International Inc (CRL)：製薬・医療：M&Aディール及び事業提携情報
    Summary Charles River Laboratories International Inc (Charles River) is a contract research organization (CRO) that provides essential products and services to accelerate the research, drug discovery and development. It offers various basic research, drug discovery and safety assessment services. Th …
  • Boule Diagnostics AB (BOUL)：医療機器：M&Aディール及び事業提携情報
    Summary Boule Diagnostics AB (Boule) is a medical device company that offers hematology diagnostic solutions. The company provides systems and consumer products for complete blood counts to non-institutional healthcare. It offers products such as blood cell counter and instruments, reagents, calibra …
  • North Central Electric Cooperative, Inc.：発電所・企業SWOT分析
    North Central Electric Cooperative, Inc. - Power Plants and SWOT Analysis, 2017 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, informa …
  • Riverbed Technology, Inc.：企業の戦略的SWOT分析
    Riverbed Technology, Inc. - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products …
  • Midshire Catering Services Limited：企業の戦略・SWOT・財務情報
    Midshire Catering Services Limited - Strategy, SWOT and Corporate Finance Report Summary Midshire Catering Services Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, p …
  • Vect-Horus SAS：製薬・医療：M&Aディール及び事業提携情報
    Summary Vect-Horus SAS (Vect-Horus) is a biotechnology company that designs and develops peptide-based vectors to facilitate the delivery of drugs or imaging agents into organs including the brain and tumors. The company combines molecules of interest to peptide-vectors that targets receptor mediate …
  • EyePoint Pharmaceuticals Inc (PSDV)：医療機器：M&Aディール及び事業提携情報
    Summary EyePoint Pharmaceuticals Inc (EyePoint), formerly pSivida Corp, is a biopharmaceutical company that provides development of miniaturized, sustained-release drug delivery products and technologies. The company offers products such as iluvien, retisert and durasert, among others. Its durasert …
  • China Huaneng Group：電力：M&Aディール及び事業提携情報
    Summary China Huaneng Group (CHNG) is a state-owned power generation company. It invests, develops, constructs, operates and manages power sources in China. The company develops coal-fired, hydro, wind, solar, nuclear and natural gas-fired power projects. CHNG also involved in the development, inves …
  • Daktronics Inc (DAKT)：企業の財務・戦略的SWOT分析
    Daktronics Inc (DAKT) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Eco (Atlantic) Oil & Gas Ltd (EOG)：企業の財務・戦略的SWOT分析
    Summary Eco (Atlantic) Oil & Gas Ltd (Eco) is an oil and gas exploration and development company. The company’s business activities include acquisition, identification, and development of upstream petroleum projects across Africa. The company's projects include cooper license-PEL 030, Sharon license …
  • Pilatus Group：企業の戦略・SWOT・財務情報
    Pilatus Group - Strategy, SWOT and Corporate Finance Report Summary Pilatus Group - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …
  • BKW AG：企業の戦略・SWOT・財務分析
    BKW AG - Strategy, SWOT and Corporate Finance Report Summary BKW AG - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, prov …
  • Siem Offshore Inc (SIOFF)：石油・ガス：M&Aディール及び事業提携情報
    Summary Siem Offshore Inc (Siem Offshore), a subsidiary of Siem Industries Inc is a marine service provider that owns and operates modern offshore support vessels for the offshore oil and gas industries. The company offers shipbuilding, ordering and delivery of new vessels, acquisition of modern sec …
  • Skanska AB (SKA B)：企業の財務・戦略的SWOT分析
    Skanska AB (SKA B) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and th …
  • ProSciento Inc：製薬・医療：M&Aディール及び事業提携情報
    Summary ProSciento Inc (ProSciento), formerly Profil Institute for Clinical Research Inc is contract research organization that develops drugs and devices for the treatment of obesity, diabetes and metabolic diseases. The organization offers services such as clinical development and regulatory servi …
  • Societe Tunisienne de l’Electricite et du Gaz：電力：M&Aディール及び事業提携情報
    Summary Societe Tunisienne de l'Electricite et du Gaz (STEG) is a non-administrative Tunisian public company that produces liquefied petroleum gas (LPG) and electricity, transports, and distributes electricity and natural gas. As a public company, its mandate includes developing the natural gas netw …

◆H&Iグローバルリサーチ株式会社のお客様（例）◆